NTLA - Intellia Therapeutics Inc Stock Price, Fair Value and News

26.48USD+0.06 (+0.23%)Market Closed

Market Summary

USD26.48+0.06

Market Closed

0.23%

NTLA Stock Price

View Fullscreen

NTLA RSI Chart

NTLA Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

-5.26

Price/Sales (Trailing)

72.66

EV/EBITDA

-38.35

Price/Free Cashflow

-6.11

NTLA Price/Sales (Trailing)

NTLA Profitability

EBT Margin

-186.20%

Return on Equity

-46.86%

Return on Assets

-38.54%

Free Cashflow Yield

-16.37%

NTLA Fundamentals

NTLA Revenue

Revenue (TTM)

36.3M

Rev. Growth (Yr)

129.53%

Rev. Growth (Qtr)

41.4%

NTLA Earnings

Earnings (TTM)

-485.5M

Earnings Growth (Yr)

-4.18%

Earnings Growth (Qtr)

18.71%

Breaking Down NTLA Revenue

Last 7 days

5.6%

Last 30 days

15.6%

Last 90 days

27.6%

Trailing 12 Months

-35.4%

How does NTLA drawdown profile look like?

NTLA Financial Health

Current Ratio

9.03

NTLA Investor Care

Shares Dilution (1Y)

9.46%

Diluted EPS (TTM)

-5.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	53.5M	53.0M	51.8M	36.3M
2022	37.9M	45.3M	51.4M	52.1M
2021	51.5M	41.8M	26.8M	33.1M
2020	45.6M	50.7M	62.3M	58.0M
2019	33.4M	36.8M	40.0M	43.1M
2018	27.4M	29.1M	29.2M	30.4M
2017	20.9M	22.6M	25.1M	26.1M
2016	6.5M	9.4M	12.5M	16.5M
2015	0	0	0	6.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. John M. Leonard M.D.
WEBSITE	intelliatx.com
INDUSTRY	Biotechnology
EMPLOYEES	598

Intellia Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Intellia Therapeutics Inc? What does NTLA stand for in stocks?

NTLA is the stock ticker symbol of Intellia Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Intellia Therapeutics Inc (NTLA)?

As of Fri Jul 26 2024, market cap of Intellia Therapeutics Inc is 2.55 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NTLA stock?

You can check NTLA's fair value in chart for subscribers.

Is Intellia Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether NTLA is over valued or under valued. Whether Intellia Therapeutics Inc is cheap or expensive depends on the assumptions which impact Intellia Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NTLA.

What is Intellia Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, NTLA's PE ratio (Price to Earnings) is -5.26 and Price to Sales (PS) ratio is 72.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NTLA PE ratio will change depending on the future growth rate expectations of investors.